U.S. markets closed

Abbott Laboratories (ABL.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
101.28+0.76 (+0.76%)
At close: 6:18PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close100.52
Open102.20
Bid0.00 x 90000
Ask0.00 x 90000
Day's Range100.74 - 102.20
52 Week Range59.00 - 107.14
Volume1,135
Avg. Volume467
Market Cap180.449B
Beta (5Y Monthly)0.73
PE Ratio (TTM)40.46
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.49 (1.48%)
Ex-Dividend DateApr 14, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • MarketWatch

      Abbott says researchers in the Democratic Republic of Congo have made findings that could lead to HIV vaccine

      Medical device, diagnostics and generic drug maker Abbott said Tuesday a team of scientists has found an unusually high number of people in the Democratic Republic of Congo (DRC) with controlled HIV and said they could be a key to advancing therapies, or even developing a vaccine. The people in question test positive for HIV antibodies, but have low to non-detectable viral load counts, without using antiretroviral treatment, Abbott said in a statement. The findings were published in EbioMedicine, part of the prestigious medical journal The Lancet. They "may help researchers uncover biological trends within this population that could lead to advancements in HIV treatments -- and potentially vaccines," said the statement. Researchers from Abbott, working with Johns Hopkins University, the National Institute of Allergy and Infectious Diseases, the University of Missouri-Kansas City and the Université Protestante au Congo found the prevalence of HIV elite controllers was 2.7% to 4.3% in the DRC, compared with 0.1% to 2.0% worldwide. "The finding of a large group of HIV elite controllers in the DRC is significant considering that HIV is a life-long, chronic condition that typically progresses over time," said Tom Quinn, M.D., director of Johns Hopkins Center for Global Health, and chief of the International HIV/AIDS Research Section of the NIAID. "There have been rare instances of the infection not progressing in individuals prior to this study, but this high frequency is unusual and suggests there is something interesting happening at a physiological level in the DRC that's not random." Abbott shares were slightly higher premarket, but have gained 50% in the last 12 months, while the S&P 500 has gained 26%.

    • TheStreet.com

      Top Healthcare Stocks to Buy for 2021

      Real Money contributor Stephen Guilfoyle checks which healthcare sector names could perform best over the coming year.

    • Is Abbott (ABT) a Solid Growth Stock? 3 Reasons to Think " Yes "
      Zacks

      Is Abbott (ABT) a Solid Growth Stock? 3 Reasons to Think " Yes "

      Abbott (ABT) possesses solid growth attributes, which could help it handily outperform the market.